|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kakizoe T, Tobisu K, Takai K, Tanaka Y,
Kishi K and Teshima S: Relationship between papillary and nodular
transitional cell carcinoma in the human urinary bladder. Cancer
Res. 48:2299–2303. 1988.PubMed/NCBI
|
|
3
|
Luis NM, López-Knowles E and Real FX:
Molecular biology of bladder cancer. Clin Transl Oncol. 9:5–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fadl-Elmula I: Chromosomal changes in
uroepithelial carcinomas. Cell Chromosome. 4:12005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lindgren D, Sjödahl G, Lauss M, Staaf J,
Chebil G, Lövgren K, Gudjonsson S, Liedberg F, Patschan O, Månsson
W, et al: Integrated genomic and gene expression profiling
identifies two major genomic circuits in urothelial carcinoma. PLoS
One. 7:e388632012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nishiyama N, Arai E, Nagashio R, Fujimoto
H, Hosoda F, Shibata T, Tsukamoto T, Yokoi S, Imoto I, Inazawa J
and Kanai Y: Copy number alterations in urothelial carcinomas:
Their clinicopathological significance and correlation with DNA
methylation alterations. Carcinogenesis. 32:462–469. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hurst CD, Platt FM, Taylor CF and Knowles
MA: Novel tumor subgroups of urothelial carcinoma of the bladder
defined by integrated genomic analysis. Clin Cancer Res.
18:5865–5877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Czerniak B, Dinney C and McConkey D:
Origins of bladder cancer. Annu Rev Pathol. 11:149–174. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hartmann A, Schlake G, Zaak D, Hungerhuber
E, Hofstetter A, Hofstaedter F and Knuechel R: Occurrence of
chromosome 9 and p53 alterations in multifocal dysplasia and
carcinoma in situ of human urinary bladder. Cancer Res. 62:809–818.
2002.PubMed/NCBI
|
|
10
|
Hopman AH, Moesker O, Smeets AW, Pauwels
RP, Vooijs GP and Ramaekers FC: Numerical chromosome 1, 7, 9, and
11 aberrations in bladder cancer detected by in situ hybridization.
Cancer Res. 51:644–651. 1991.PubMed/NCBI
|
|
11
|
Platt FM, Hurst CD, Taylor CF, Gregory WM,
Harnden P and Knowles MA: Spectrum of phosphatidylinositol 3-kinase
pathway gene alterations in bladder cancer. Clin Cancer Res.
15:6008–6017. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sjödahl G, Lauss M, Gudjonsson S, Liedberg
F, Halldén C, Chebil G, Månsson W, Höglund M and Lindgren D: A
systematic study of gene mutations in urothelial carcinoma;
inactivating mutations in TSC2 and PIK3R1. PLoS One. 6:e185832011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rampias T, Vgenopoulou P, Avgeris M,
Polyzos A, Stravodimos K, Valavanis C, Scorilas A and Klinakis A: A
new tumor suppressor role for the Notch pathway in bladder cancer.
Nat Med. 20:1199–1205. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kugoh H, Ohira T and Oshimura M: Studies
of tumor suppressor genes via chromosome engineering. Cancers
(Basel). 8:42015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Uejima H, Mitsuya K, Kugoh H, Horikawa I
and Oshimura M: Normal human chromosome 2 induces cellular
senescence in the human cervical carcinoma cell line SiHa. Genes
Chromosomes Cancer. 14:120–127. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu J, Zhang Y, Yu C, Zhang P, Gu S, Wang
G, Xiao H and Li S: Bergenin inhibits bladder cancer progression
via activating the PPARγ/PTEN/Akt signal pathway. Drug Dev Res.
82:278–286. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chin L, Hahn WC, Getz G and Meyerson M:
Making sense of cancer genomic data. Genes Dev. 25:534–555. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grossman RL, Heath AP, Ferretti V, Varmus
HE, Lowy DR, Kibbe WA and Staudt LM: Toward a shared vision for
cancer genomic data. N Engl J Med. 375:1109–1112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kugoh H, Mitsuya K, Meguro M, Shigenami K,
Schulz TC and Oshimura M: Mouse A9 cells containing single human
chromosomes for analysis of genomic imprinting. DNA Res. 6:165–172.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eriksson P, Aine M, Veerla S, Liedberg F,
Sjödahl G and Höglund M: Molecular subtypes of urothelial carcinoma
are defined by specific gene regulatory systems. BMC Med Genomics.
8:252015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hustler A, Eardley I, Hinley J, Pearson J,
Wezel F, Radvanyi F, Baker SC and Southgate J: Differential
transcription factor expression by human epithelial cells of buccal
and urothelial derivation. Exp Cell Res. 369:284–294. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Warrick JI, Walter V, Yamashita H, Chung
E, Shuman L, Amponsa VO, Zheng Z, Chan W, Whitcomb TL, Yue F, et
al: FOXA1, GATA3 and PPARγ cooperate to drive luminal subtype in
bladder cancer: A molecular analysis of established human cell
lines. Sci Rep. 6:385312016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Osei-Amponsa V, Buckwalter JM, Shuman L,
Zheng Z, Yamashita H, Walter V, Wildermuth T, Ellis-Mohl J, Liu C,
Warrick JI, et al: Hypermethylation of FOXA1 and allelic loss of
PTEN drive squamous differentiation and promote heterogeneity in
bladder cancer. Oncogene. 39:1302–1317. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Y, Ishiguro H, Kawahara T, Kashiwagi E,
Izumi K and Miyamoto H: Loss of GATA3 in bladder cancer promotes
cell migration and invasion. Cancer Biol Ther. 15:428–435. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng S, Qian K, Wang Y, Wang G, Liu X,
Xiao Y and Wang X: PPARγ inhibition regulates the cell cycle,
proliferation and motility of bladder cancer cells. J Cell Mol Med.
23:3724–3736. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hau AM, Nakasaki M, Nakashima K, Krish G
and Hansel DE: Differential mTOR pathway profiles in bladder cancer
cell line subtypes to predict sensitivity to mTOR inhibition. Urol
Oncol. 35:593–599. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin MS, Huang JX, Chen WC, Zhang BF, Fang
J, Zhou Q, Hu Y and Gao HJ: Expression of PPARγ and PTEN in human
colorectal cancer: An immunohistochemical study using tissue
microarray methodology. Oncol Lett. 2:1219–1224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y,
Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK,
et al: Pembrolizumab as second-line therapy for advanced urothelial
carcinoma. N Engl J Med. 376:1015–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Choi W, Czerniak B, Ochoa A, Su X,
Siefker-Radtke A, Dinney C and McConkey DJ: Intrinsic basal and
luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol.
11:400–410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Robertson AG, Kim J, Al-Ahmadie H,
Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA,
Akbani R, et al: Comprehensive molecular characterization of
muscle-invasive bladder cancer. Cell. 171:540–556.e25. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sonenberg N and Hinnebusch AG: New modes
of translational control in development, behavior, and disease. Mol
Cell. 28:721–729. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou Y, Liang H, Liao Z, Wang Y, Hu X,
Chen X, Xu L and Hu Z: miR-203 enhances let-7 biogenesis by
targeting LIN28B to suppress tumor growth in lung cancer. Sci Rep.
7:426802017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lemberger T, Braissant O, Juge-Aubry C,
Keller H, Saladin R, Staels B, Auwerx J, Burger AG, Meier CA and
Wahli W: PPAR tissue distribution and interactions with other
hormone-signaling pathways. Ann N Y Acad Sci. 804:231–251. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cheng S, Wang G, Wang Y, Cai L, Qian K, Ju
L, Liu X, Xiao Y and Wang X: Fatty acid oxidation inhibitor
etomoxir suppresses tumor progression and induces cell cycle arrest
via PPARγ-mediated pathway in bladder cancer. Clin Sci (Lond).
133:1745–1758. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cao R, Wang G, Qian K, Chen L, Ju L, Qian
G, Wu CL, Dan HC, Jiang W, Wu M, et al: TM4SF1 regulates apoptosis,
cell cycle and ROS metabolism via the PPARγ-SIRT1 feedback loop in
human bladder cancer cells. Cancer Lett. 414:278–293. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cao R, Wang G, Qian K, Chen L, Qian G, Xie
C, Dan HC, Jiang W, Wu M, Wu CL, et al: Silencing of HJURP induces
dysregulation of cell cycle and ROS metabolism in bladder cancer
cells via PPARγ-SIRT1 feedback loop. J Cancer. 8:2282–2295. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang G, Cao R, Wang Y, Qian G, Dan HC,
Jiang W, Ju L, Wu M, Xiao Y and Wang X: Simvastatin induces cell
cycle arrest and inhibits proliferation of bladder cancer cells via
PPARγ signalling pathway. Sci Rep. 6:357832016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mylona E, Giannopoulou I, Diamantopoulou
K, Bakarakos P, Nomikos A, Zervas A and Nakopoulou L: Peroxisome
proliferator-activated receptor gamma expression in urothelial
carcinomas of the bladder: Association with differentiation,
proliferation and clinical outcome. Eur J Surg Oncol. 35:197–201.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cairns P, Mao L, Merlo A, Lee DJ, Schwab
D, Eby Y, Tokino K, van der Riet P, Blaugrund JE and Sidransky D:
Rates of p16 (MTS1) mutations in primary tumors with 9p loss.
Science. 265:415–417. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Williamson MP, Elder PA, Shaw ME, Devlin J
and Knowles MA: p16 (CDKN2) is a major deletion target at 9p21 in
bladder cancer. Hum Mol Genet. 4:1569–1577. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ploussard G, Dubosq F, Soliman H, Verine
J, Desgrandchamps F, De Thé H and Mongiat-Artus P: Prognostic value
of loss of heterozygosity at chromosome 9p in non-muscle-invasive
bladder cancer. Urology. 76:513.e13–e18. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Krüger S, Mahnken A, Kausch I and Feller
AC: P16 immunoreactivity is an independent predictor of tumor
progression in minimally invasive urothelial bladder carcinoma. Eur
Urol. 47:463–467. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bartoletti R, Cai T, Nesi G, Roberta
Girardi L, Baroni G and Dal Canto M: Loss of P16 expression and
chromosome 9p21 LOH in predicting outcome of patients affected by
superficial bladder cancer. J Surg Res. 143:422–427. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang Z, Xu H, Ji J, Shi X, Lyu J, Zhu Y,
Yu H and Wang F: Heterogeneity of PTEN and PPAR-γ in cancer and
their prognostic application to bladder cancer. Exp Ther Med.
18:3177–3183. 2019.PubMed/NCBI
|
|
46
|
Qi DL, Ohhira T, Fujisaki C, Inoue T, Ohta
T, Osaki M, Ohshiro E, Seko T, Aoki S, Oshimura M and Kugoh H:
Identification of PITX1 as a TERT suppressor gene located on human
chromosome 5. Mol Cell Biol. 31:1624–1636. 2011. View Article : Google Scholar : PubMed/NCBI
|
